Non Small Cell Lung Cancer - osimertinib - CYP1A2 rs2069514

Association details:

Biomarker:	CYP1A2 rs2069514
Cancer:	Non Small Cell Lung Cancer
Drug:	Tagrisso (osimertinib) (EGFR inhibitor)
Direction:	Resistant

Evidence:

Evidence Level:

Resistant: C3 – Early Trials

Source:

Front Pharmacol

Title:

CYP450 and drug efflux transporters polymorphism influence clinical outcomes of Thai osimertinib-treated non-small cell lung cancer patients

Published date:

11/29/2023

Excerpt:

This retrospective and prospective cohort study enrolled 63 Thai patients with NSCLC treated with 80 mg of osimertinib once daily as monotherapy….In addition, we found two SNPs (rs2069514 in CYP1A2 and rs1057910 in CYP2C9) that significantly decreased the median TTF, and two SNPs (rs28399433 in CYP2A6 and rs1057910 in CYP2C9) that significantly decreased the median progression-free survival (PFS).

DOI:

10.3389/fphar.2023.1222435